Make-up of Australian HTA review committee announced

11 April 2022

The make-up of Australia’s Health Technology Assessment (HTA) Review Reference Committee has been announced.

Australia’s HTA Review has a goal to reduce the time that it takes for the country’s patients to access new health technologies. It will undertake the first major review and reform of the HTA system in 30 years.

"The outcomes must lead to health system improvement and meet future patient needs and demands"The committee will be independently chaired by former senior public servant and policymaker, Peter Boxall. Other members are John Young, former chairman of the Medicines Australia trade group, blood cancer researcher and hematologist Andrew Roberts, and Andrew Wilson, chairman of the Pharmaceutical Benefits Advisory Committee.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK